ArticleFrontiers in public health2025
Co-use of opioids and cannabis versus single-substance use: a national analysis of US adults.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While many studies have explored the relationship between cannabis and opioid use, few have examined how individuals who use opioids only, cannabis only, or both substances differ in terms of sociodemographic and health-related characteristics. Understanding these differences may support the development of clinical and public health strategies addressing substance use patterns. Methods: We analyzed data from the 2015-2022 National Survey on Drug Use and Health (NSDUH), focusing on US adults (≥18 years) who reported past-year medical use of prescription opioids and/or cannabis. Individuals were categorized into three mutually exclusive groups: opioid-only, cannabis-only, and opioid-cannabis co-use (OC). Descriptive statistics and weighted multinomial logistic regression models were used to compare characteristics across groups, adjusting for the complex survey design. Results: Among 134,402 adults, 49.5% used opioids only, 35.3% used cannabis only, and 15.2% reported co-use. Co-use was more common among younger adults, individuals with lower income, and those experiencing psychological distress. The impact of depression on the relative risk ratio (RRR) for opioid use only, relative to co-use, was similar to those on the RRR for cannabis use only (RRR = 0.52; 95% CI: 0.49-0.56). However, for many characteristics, the RRR of opioid use only, vs. co-use, differed from that of cannabis use only, vs. co-use. Compared to co-users, individuals in the opioid-only group were more likely to be older, women, and reside in large-metro areas. In contrast, individuals in the cannabis-only group were more likely to be younger, men, report better health status, and reside in non-metro regions. Conclusion: Individuals who use opioids only, cannabis only, or both substances differ significantly across demographic, socioeconomic, and health-related factors. These distinctions highlight the need for tailored clinical guidance and public health responses that account for co-use patterns and geographic context to support safer pain management and substance use care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.